

## Patrys Data To Be Presented at ASH International Conference

- PAT-SM6 clinical trial data to be presented at prestigious American Society of Hematology conference
- Acceptance of poster abstract reflects interest in the clinical trial data by the global myeloma community

**Melbourne, Australia; 10 October, 2013:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company has announced that results related to its novel anti-cancer PAT-SM6 lead clinical candidate and data generated to date from the ongoing clinical trial in multiple myeloma has been accepted for presentation at the 55<sup>th</sup> ASH Annual Meeting and Exposition, run by the American Society of Hematology in New Orleans, to be held on 7- 10 December 2013.

The results from further *in vitro* and *in vivo* preclinical work, in addition to preliminary data from the trial investigating the use of PAT-SM6 in relapsed/refractory multiple myeloma patients will be presented by lead clinical investigator Dr. Leo Rasche of the Department of Haematology and Oncology, University Hospital of Würzburg. The poster is titled "A monoclonal IgM antibody with specificity to heat shock protein GRP78/BIP shows anti-myeloma activity *in vitro* and *in vivo*, synergy in combination with Lenalidomide and safety in a pilot Phase I study".

Patrys' abstract for the ASH annual meeting will be published in a special online-only issue of *Blood*, the American Society of Hematology's official journal on the following website [http://bloodjournal.hematologylibrary.org/site/misc/ASH\\_Meeting\\_Abstracts\\_Info.xhtml](http://bloodjournal.hematologylibrary.org/site/misc/ASH_Meeting_Abstracts_Info.xhtml). The abstract will be available on-line in December 2013.

Patrys CEO, Dr. Marie Roskrow, said: "The presentation of the data at this international conference and the progression of evaluation of PAT-SM6 anti-myeloma activity *in vivo* is a significant step forward for Patrys' development programme towards use of this novel antibody in multiple myeloma. New treatments for multiple myeloma are urgently needed as myeloma remains incurable for most patients".

**-Ends-**

**For further information, please contact:**

Patrys Limited:

Dr. Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:

Rebecca Wilson  
Buchan Consulting  
P: 0417 382 391  
[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Patrys Media:

Shevaun Cooper  
Buchan Consulting  
P: +61 3 9866 4722  
[scooper@buchanwe.com.au](mailto:scooper@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that qualify for both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to multiple myeloma PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. Patrys' PAT-SM6 is currently showing convincing evidence of potential therapeutic benefit in its ongoing Phase I/IIa clinical trial in patients with relapsed and refractory multiple myeloma. Patrys has also successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma.

**About Multiple Myeloma:**

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics. There is an estimated 200,000 cases worldwide and the incidence is increasing. The five-year survival of patients is approximately 30% (at 10 years ~20%). Despite new marketed therapies, multiple myeloma remains largely incurable and fatal. The multiple myeloma market is dominated by three major products: Revlimid, Velcade and Thalidomide with combined net sales greater than US\$6 Billion in 2012.